🔎 Trials Near Me

Home › Attention Deficit Hyperactivity Disorder › NCT07203092

Effects of Transcranial Photobiomodulation in ADHD

Recruiting

Effects of Transcranial Photobiomodulation on Cognition and Brain Metabolism in Adults With ADHD

Who can join

Ages 18 to 44 · All sexes

Full eligibility criteria
Inclusion Criteria:

* English-speaking
* Adults of any sex
* Age range: 18-44 years
* Any ethnic/racial background
* Medical history of ADHD
* Participants may either be on a stable ADHD medication regimen (with no changes within two weeks prior to the study) or not taking medication.

Exclusion Criteria:

* Currently pregnancy
* Any sham or active photobiomodulation treatment within the past five weeks.

About the study

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM).

The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

What is being tested

Sponsor: Francisco Gonzalez-Lima, PhD · Participants: 140 · Started: Sep 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07203092

Locations in the U.S.

TexasThe University of Texas at Austin, Austin

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.